Evidence map›Paper›PMID 35096289›Full record

ReviewIranian journal of basic medical sciences2021

Mesenchymal stem cells in cancer therapy; the art of harnessing a foe to a friend.

Mehdi Karimi-Shahri, Hossein Javid, Alireza Sharbaf Mashhad, Shaghayegh Yazdani, Seyed Isaac Hashemy

Abstract readReview
In one paragraph

Review in Iranian journal of basic medical sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Stem Cell Therapy for the Management of Type 1 Diabetes: Advances and Perspectives.Endocrine, metabolic & immune disorders drug targets · 2024
    Review
  8. The role of MSCs and CAR-MSCs in cellular immunotherapy.Cell communication and signaling : CCS · 2023
    Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mehdi Karimi-ShahriDepartment of Pathology, School of Medicine, Gonabad University of Medical Sciences, Gonabad, Iran.
Hossein JavidDepartment of Medical Laboratory Sciences, Varastegan Institute for Medical Sciences, Mashhad, Iran.
Alireza Sharbaf MashhadDepartment of Medical Laboratory Sciences, Mashhad University of Medical Sciences, Mashhad, Iran.
Shaghayegh YazdaniDepartment of Medical Laboratory Sciences, Ilam Institute for Medical Sciences, Ilam, Iran.
Seyed Isaac HashemyDepartment of Clinical Biochemistry, Faculty of Medicine, Mashhad University of ‎Medical Sciences, Mashhad, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

For a long time, mesenchymal stem cells (MSCs) were discussed only as stem cells which could give rise to different types of cells. However, when it became clear that their presence in the tumor microenvironment (TME) was like a green light for tumorigenesis, they emerged from the ashes. This review was arranged to provide a comprehensive and precise description of MSCs' role in regulating tumorigenesis and to discuss the dark and the bright sides of cancer treatment strategies using MSCs. To gather the details about MSCs, we made an intensive literature review using keywords, including MSCs, tumor microenvironment, tumorigenesis, and targeted therapy. Through transferring cytokines, growth factors, and microRNAs, MSCs maintain the cancer stem cell population, increase angiogenesis, provide a facility for cancer metastasis, and shut down the anti-tumor activity of the immune system. Although MSCs progress tumorigenesis, there is a consensus that these cells could be used as a vehicle to transfer anti-cancer agents into the tumor milieu. This feature opened a new chapter in MSCs biology, this time from the therapeutic perspective. Although the data are not sufficient, the advent of new genetic engineering methods might make it possible to engage these cells as Trojan horses to eliminate the malignant population. So many years of investigation showed that MSCs are an important group of cells, residing in the TME, studying the function of which not only could add a delicate series of information to the process of tumorigenesis but also could revolutionize cancer treatment strategies.

Indexed as

CarcinogenesisMesenchymal stem cellsMolecular targeted – therapiesNeoplasmTumor microenvironment

Identifiers

PMID35096289
PMCPMC8769515

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.